ID

32060

Beskrivning

Study ID: 103992 Clinical Study ID: 103992 Study Title: Evaluate immunogenicity, reactogenicity & safety of 2 doses of GSK Biologicals’ oral live attenuated HRV vaccine (RIX4414 at 106.5 CCID50) when given concomitantly with OPV versus given alone (HRV vaccine dose given 15 days after the OPV dose) in healthy infants in Bangladesh Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00139334 https://clinicaltrials.gov/ct2/show/NCT00139334 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Rotavirus Vaccine Trade Name: Rotarix Study Indication: Haemophilus influenzae type b; Neisseria Meningitidis This form details Elimination Criteria. They need to be checked at each visit prior to any other procedure, starting form Visit 2. Visit 2 -> Timing: Day 30, Age: 10 weeks +/- 1 week Visit 3 -> Timing: Day 45, Age: 12 weeks +/- 1 week Visit 4 -> Timing: Day 60, Age: 14 weeks +/- 1 week Visit 5 -> Timing: Day 75, Age: 16 weeks +/- 1 week Visit 6 -> Timing: Day 105, Age: 20 weeks +/- 1 week

Länk

https://clinicaltrials.gov/ct2/show/NCT00139334

Nyckelord

Versioner (1)

1. 2018-10-16 2018-10-16 - Sarah Riepenhausen

Rättsinnehavare

GlaxoSmithKline

Uppladdad den

16 oktober 2018

DOI

För en begäran logga in.

Licens